Exin Therapeutics GTM brain

category

market profile

• text: Neurotherapeutic discovery faces a translation challenge between preclinical neural activity and human disease outcomes.
• text: Exin describes a research loop combining computational target identification and experiments in its Manila data foundry, with epilepsy as its initial focus.
• text: Neuro-focused and AI-driven discovery companies compete for assets and partnerships, alongside more advanced epilepsy drug developers.

personas

• title: Pharma neuroscience business development leader
  pains:

  • Finding differentiated early CNS programs with credible biological evidence
  • Assessing whether animal findings can translate to human patients
• title: Neuroscience discovery research director
  pains:

  • Connecting circuit dysfunction to testable therapeutic targets
  • Prioritizing costly experiments when evidence spans species and data types
• title: Epilepsy translational research funder
  pains:

  • Identifying promising approaches for patients with limited options
  • Evaluating preclinical progress without confusing it for clinical efficacy

icp

• text: Potential partners include pharmaceutical and biotech organizations with neuroscience discovery or licensing programs; current partnership terms are not established.
• text: Epilepsy and neural circuit research organizations are plausible scientific collaborators, not confirmed customers.

objections

• objection: Will the preclinical findings translate to patients?
  response: Request validation of the cross-species approach, independent replication and current development-stage data; model predictions are not clinical proof.
• objection: Is the platform available to external partners?
  response: Ask the company about collaboration scope, rights and milestones; a standard offer or price is not established.
• objection: How are target hypotheses tested?
  response: Review the reported research workflow and ask for relevant experimental results and reproducibility.

competitors

• name: Cerevance
  why: Neuroscience-focused target discovery company pursuing CNS therapeutics.
• name: Recursion
  why: AI-driven drug discovery company with automated experimental capabilities.
• name: Xenon Pharmaceuticals
  why: Develops epilepsy therapies and competes for attention and resources in the therapeutic area at a later stage.

influencers

• name: Gabriel Ocana Santero
  url: https://www.linkedin.com/in/gabriel-ocana-santero-85b41819a
  why: Exin co-founder and CEO publicly discusses his work.
• name: Ivan Lazarte
  url: https://aventure.vc/people/ivan-lazarte-exin
  why: Co-founder and neuroscience research leader.

keywords

• AI neurotherapeutics discovery
• epilepsy drug discovery
• neural circuit therapeutic targets
• cross species neuroscience models
• CNS target discovery partnership
• in vivo neuroscience discovery

voice

• Scientific and mechanism-oriented
• Research-led and ambitious

signals

• text: A pharma neuroscience team seeks external preclinical epilepsy programs or target discovery collaborations.
• text: A research group needs stronger translation of neural activity findings across species.

pricing

motion

channels

• scientific publications
• LinkedIn
• biotech press

confidence

Founders

• name: Gabriel Ocana Santero
  title: Founder/CEO
  role: CEO
  bio: Neuroscientist with a background in biochemistry and research on gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. Earned MSc in Neuroscience and PhD in Pharmacology at Oxford Uni, focusing on neurodevelopment and the effects of SSRI anti-depressants on early patterns of neural activity. Used neuroAI models at the Gatsby Unit (UCL) to study serotonin’s role in cognition. Currently developing gene therapies for neurological conditions.
• name: Marko Tvrdic
  title: Founder/COO
  role: COO
  bio: Co-founder at Exin Therapeutics.